"10.1371_journal.pone.0065088","plos one","2013-06-12T00:00:00Z","Philip R Corlett; Victoria Cambridge; Jennifer M Gardner; Jennifer S Piggot; Danielle C Turner; Jessica C Everitt; Fernando Sergio Arana; Hannah L Morgan; Amy L Milton; Jonathan L Lee; Michael R F Aitken; Anthony Dickinson; Barry J Everitt; Anthony R Absalom; Ram Adapa; Naresh Subramanian; Jane R Taylor; John H Krystal; Paul C Fletcher","Department of Psychiatry, Ribicoff Research Facility, Yale University, New Haven, Connecticut, United States of America; Brain Mapping Unit, Department of Psychiatry, University of Cambridge, School of Clinical Medicine, Addenbrookes Hospital, Cambridge, United Kingdom; University of Cambridge, School of Clinical Medicine, Addenbrookes Hospital, Cambridge, United Kingdom; Department of Psychology, University of Cambridge, Cambridge, United Kingdom; University of Birmingham, School of Psychology, Edgbaston, Birmingham, United Kingdom; Department of Anesthesiology, University Medical Center Groningen, Groningen University, Groningen, The Netherlands; Division of Anaesthesia, School of Clinical Medicine, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom; Cambridgeshire and Peterborough NHS Foundation Trust, Elizabeth House, Fulbourn Hospital, Cambridge, United Kingdom","Conceived and designed the experiments: PRC VC PCF JRT JHK BJE AD MRFA JLL ALM. Performed the experiments: PRC VC JMG JSP DCT JCE FSA HLM ARA RA. Analyzed the data: PRC MRFA PCF NS ARA RA. Contributed reagents/materials/analysis tools: NS. Wrote the paper: PRC PCF JRT JHK JLL BJE ALM.","Philip Corlett reports receiving research support from AstraZeneca Pharmaceuticals, LP and consulting for Pfizer Pharmaceuticals. John Krystal reports consulting for AstraZeneca Pharmaceuticals, LP, Cypress Bioscience, Inc., HoustonPharma, Schering-Plough Research Institute, Shire Pharmaceuticals, and Pfizer Pharmaceuticals; Advisory Boards: Bristol-Myers Squibb, Eli Lilly and Co., Forest Laboratories, GlaxoSmithKline, Lohocla Research Corporation, Merz Pharmaceuticals, Takeda Industries, and Transcept Pharmaceuticals, Inc. Exercisable Warrant Options: Tetragenex Pharmaceuticals Inc.; Research Support: Janssen Research Foundation; Pending Patents: glutamatergic agents for psychiatric disorders (depression, OCD), antidepressant effects of oral ketamine, and oral ketamine for depression. Paul Fletcher has received consultancy fees from GlaxoSmithKline and an honorarium for a lecture from Astra Zeneca. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.",NA,NA,NA,"2013","06","Philip R Corlett","PRC",19,TRUE,10,10,6,7,TRUE,TRUE,FALSE,0,NA,FALSE
